ClinConnect ClinConnect Logo
Search / Trial NCT06633692

Female Pelvic Blood Flow Under Simulated Microgravity

Launched by CEREN UNAL · Oct 7, 2024

Trial Information

Current as of July 04, 2025

Recruiting

Keywords

Microgravity Female Pelvic Blood Flow Doppler Ultrasound

ClinConnect Summary

This clinical trial is studying how simulated microgravity affects blood flow in the pelvic area of healthy women. Researchers want to understand how space travel might impact women's health, particularly the blood circulation to reproductive organs like the uterus and ovaries. To do this, they will use a method called Doppler velocimetry, which helps measure blood flow. Participants will first lie flat (the supine position) to establish a baseline measurement of their blood flow. Then, they will be placed in a head-down tilt position, which simulates the effects of microgravity, and blood flow will be measured again.

Women aged 18 to 44 who are generally healthy can join this study. However, those who have had a hysterectomy (removal of the uterus) or oophorectomy (removal of the ovaries), are pregnant, have certain reproductive health issues, or heart diseases cannot participate. Throughout the trial, participants will have their vital signs, like blood pressure and heart rate, monitored. This study is important as it helps us learn more about how space travel may affect women's health, especially with upcoming missions to the Moon and Mars.

Gender

FEMALE

Eligibility criteria

  • Inclusion Criteria:
  • 18-44 years old healthy female individuals
  • Exclusion Criteria:
  • History of hysterectomy and/or oophorectomy
  • Pregnancy
  • Premature ovarian insufficiency
  • Women with reproductive tract pathologies
  • Cardiovascular diseases

About Ceren Unal

Ceren Unal is a dedicated clinical trial sponsor specializing in the design, management, and execution of innovative clinical research initiatives. With a strong commitment to advancing medical knowledge and improving patient outcomes, Ceren Unal collaborates with a diverse range of stakeholders, including pharmaceutical companies, academic institutions, and healthcare providers. The organization emphasizes rigorous scientific methodology and ethical standards in its trials, ensuring the highest quality of data collection and analysis. Through its strategic approach and expertise in clinical development, Ceren Unal aims to accelerate the delivery of new therapies to the market, ultimately enhancing the standard of care for patients worldwide.

Locations

Istanbul, , Turkey

Patients applied

0 patients applied

Trial Officials

Afak Durur Karakaya, M.D.

Principal Investigator

Koç University

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported